BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong SY, Dixon R, Martinez Pazos V, Gnjatic S, Colombel JF, Cadwell K; ICARUS-IBD Working Group. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology 2021;161:715-718.e4. [PMID: 33887219 DOI: 10.1053/j.gastro.2021.04.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Zacharopoulou E, Orfanoudaki E, Tzouvala M, Tribonias G, Kokkotis G, Kitsou V, Almpani F, Christidou A, Viazis N, Mantzaris GJ, Tsafaridou M, Karmiris K, Theodoropoulou A, Papathanasiou E, Zampeli E, Michopoulos S, Tigkas S, Michalopoulos G, Laoudi E, Karatzas P, Mylonas I, Kyriakos N, Liatsos C, Kafetzi T, Theocharis G, Taka S, Panagiotopoulou K, Koutroubakis IE, Bamias G. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. Inflamm Bowel Dis 2022:izac068. [PMID: 35394529 DOI: 10.1093/ibd/izac068] [Reference Citation Analysis]
2 James D, Jena A, Bharath PN, Choudhury A, Singh AK, Sebastian S, Sharma V. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis. Dig Liver Dis 2022:S1590-8658(22)00210-9. [PMID: 35382972 DOI: 10.1016/j.dld.2022.03.005] [Reference Citation Analysis]
3 Lin S, Lau LH, Chanchlani N, Kennedy NA, Ng SC. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2022:gutjnl-2021-326784. [PMID: 35477864 DOI: 10.1136/gutjnl-2021-326784] [Reference Citation Analysis]
4 Pozdnyakova V, Botwin GJ, Sobhani K, Prostko J, Braun J, Mcgovern DPB, Melmed GY, Appel K, Banty A, Feldman E, Ha C, Kumar R, Lee S, Rabizadeh S, Stein T, Syal G, Targan S, Vasiliauskas E, Ziring D, Debbas P, Hampton M, Mengesha E, Stewart JL, Frias EC, Cheng S, Ebinger J, Figueiredo JC, Boland B, Charabaty A, Chiorean M, Cohen E, Flynn A, Valentine J, Fudman D, Horizon A, Hou J, Hwang C, Lazarev M, Lum D, Fausel R, Reddy S, Mattar M, Metwally M, Ostrov A, Parekh N, Raffals L, Sheibani S, Siegel C, Wolf D, Younes Z. Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease. Gastroenterology 2021;161:2041-2043.e1. [PMID: 34391771 DOI: 10.1053/j.gastro.2021.08.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
5 Zeng H, Wang S, Chen L, Shen Z. Biologics for Psoriasis During the COVID-19 Pandemic. Front Med (Lausanne) 2021;8:759568. [PMID: 34938746 DOI: 10.3389/fmed.2021.759568] [Reference Citation Analysis]
6 Garcillán B, Salavert M, Regueiro JR, Díaz-castroverde S. Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. Vaccines 2022;10:297. [DOI: 10.3390/vaccines10020297] [Reference Citation Analysis]
7 Melgaço FG, Azamor T, Villar LM, Ano Bom APD, Melgaço JG. Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn's Disease after COVID-19 Vaccination: A Twin Case. Viruses 2021;13:2143. [PMID: 34834950 DOI: 10.3390/v13112143] [Reference Citation Analysis]
8 Vollenberg R, Tepasse P, Lorentzen E, Nowacki TM. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study. JPM 2022;12:694. [DOI: 10.3390/jpm12050694] [Reference Citation Analysis]
9 Marra AR, Kobayashi T, Suzuki H, Alsuhaibani M, Tofaneto BM, Bariani LM, Auler MA, Salinas JL, Edmond MB, Doll M, Kutner JM, Pinho JRR, Rizzo LV, Miraglia JL, Schweizer ML. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis. J Infect 2022:S0163-4453(21)00658-7. [PMID: 34982962 DOI: 10.1016/j.jinf.2021.12.035] [Reference Citation Analysis]
10 Tepasse PR, Vollenberg R, Nowacki TM. Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand? Life (Basel) 2021;11:1220. [PMID: 34833096 DOI: 10.3390/life11111220] [Reference Citation Analysis]
11 Sakuraba A, Luna A, Micic D. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. Gastroenterology 2022;162:88-108.e9. [PMID: 34599933 DOI: 10.1053/j.gastro.2021.09.055] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Melmed GY, Botwin GJ, Sobhani K, Li D, Prostko J, Figueiredo J, Cheng S, Braun J, McGovern DPB. Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease. Ann Intern Med 2021. [PMID: 34633830 DOI: 10.7326/M21-2483] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Lee YJ, Kim SE, Park YE, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC, Choi M, Myung SJ; Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases. [SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID]. Korean J Gastroenterol 2021;78:117-28. [PMID: 34446634 DOI: 10.4166/kjg.2021.110] [Reference Citation Analysis]
14 Shehab M, Alrashed F, Alfadhli A, Alotaibi K, Alsahli A, Mohammad H, Cherian P, Al-Khairi I, Alphonse Thanaraj T, Channanath A, Ali H, Abu-Farha M, Abubaker J, Al-Mulla F. Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies. Vaccines (Basel) 2021;9:1471. [PMID: 34960217 DOI: 10.3390/vaccines9121471] [Reference Citation Analysis]
15 Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. J Am Acad Dermatol 2021:S0190-9622(21)02217-9. [PMID: 34363909 DOI: 10.1016/j.jaad.2021.07.054] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology 2021:S0016-5085(21)03701-X. [PMID: 34717923 DOI: 10.1053/j.gastro.2021.10.029] [Reference Citation Analysis]
17 Agrati C, Di Cosimo S, Fenoglio D, Apolone G, Ciceri F, Ciliberto G, Baldanti F, Costantini M, Giannarelli D, Ippolito G, Locatelli F, Mantovani A, Morrone A, Tagliavini F, Uccelli A, Zinzani PL, Silvestris N, Rescigno M. COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. Front Immunol 2021;12:704110. [PMID: 34447374 DOI: 10.3389/fimmu.2021.704110] [Reference Citation Analysis]
18 Spencer EA, Klang E, Dolinger M, Pittman N, Dubinsky MC. Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients. Inflamm Bowel Dis 2021;27:1862-4. [PMID: 34427638 DOI: 10.1093/ibd/izab194] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wagner A, Garner-spitzer E, Schötta A, Orola M, Wessely A, Zwazl I, Ohradanova-repic A, Weseslindtner L, Tajti G, Gebetsberger L, Kratzer B, Tomosel E, Kutschera M, Tobudic S, Pickl WF, Kundi M, Stockinger H, Novacek G, Reinisch W, Zielinski C, Wiedermann U. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. Front Immunol 2022;13:889138. [DOI: 10.3389/fimmu.2022.889138] [Reference Citation Analysis]
20 Pokryszka J, Wagner A, Wiedermann U, Tobudic S, Herkner H, Winkler S, Brehovsky S, Reinisch W, Novacek G. Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. Vaccines 2022;10:759. [DOI: 10.3390/vaccines10050759] [Reference Citation Analysis]
21 Vollenberg R, Tepasse P, Kühn JE, Hennies M, Strauss M, Rennebaum F, Schomacher T, Boeckel G, Lorentzen E, Bokemeyer A, Nowacki TM. Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2. Biomedicines 2022;10:171. [DOI: 10.3390/biomedicines10010171] [Reference Citation Analysis]
22 Miyoshi J, Matsuura M, Hisamatsu T. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. Expert Opin Drug Saf 2021. [PMID: 34511011 DOI: 10.1080/14740338.2021.1980536] [Reference Citation Analysis]
23 Bodini G, Giuliana E, Giberti I, Guarona G, Benvenuto F, Ferretti E, Demarzo MG, Da Rin G, Icardi G, Giannini EG. Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment. Gastrointestinal Disorders 2022;4:77-83. [DOI: 10.3390/gidisord4020009] [Reference Citation Analysis]
24 Galmiche S, Luong Nguyen LB, Tartour E, de Lamballerie X, Wittkop L, Loubet P, Launay O. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect 2021:S1198-743X(21)00566-8. [PMID: 35020589 DOI: 10.1016/j.cmi.2021.09.036] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Levartovsky A, Ben-Horin S. Anti-TNF Therapy During the SARS-CoV-2 Pandemic: Friend or Foe? J Crohns Colitis 2021:jjab167. [PMID: 34626174 DOI: 10.1093/ecco-jcc/jjab167] [Reference Citation Analysis]
26 Chanchlani N, Lin S, Chee D, Hamilton B, Nice R, Zehra A, Bewshea C, Cipriano B, Derikx LAAP, Dunlop A, Greathead L, Griffiths RL, Ibraheim H, Kelleher P, Kok KB, Lees CW, MacDonald J, Sebastian S, Smith PJ, McDonald TJ, Irving PM, Powell N, Kennedy NA, Goodhand JR, Ahmad T. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients. J Crohns Colitis 2021:jjab153. [PMID: 34473254 DOI: 10.1093/ecco-jcc/jjab153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
27 Selim R, Wellens J, Marlow L, Satsangi JJ. SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy. Lancet Gastroenterol Hepatol 2021;6:989. [PMID: 34655528 DOI: 10.1016/S2468-1253(21)00347-2] [Reference Citation Analysis]
28 Törüner M, Kalkan İH, Akyüz F, Tezel A, Çelik AF. Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic. Turk J Gastroenterol 2021;32:488-92. [PMID: 34405814 DOI: 10.5152/tjg.2021.280721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Ben-Tov A, Banon T, Chodick G, Kariv R, Assa A, Gazit S; Collaborators of the Maccabi Institute for Research & Innovation COVID-19 Task Force. BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign. Gastroenterology 2021:S0016-5085(21)03233-9. [PMID: 34224740 DOI: 10.1053/j.gastro.2021.06.076] [Reference Citation Analysis]
30 Ramirez GA, Asperti C, Cucca V, Yacoub MR. Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases. Vaccines (Basel) 2021;9:1147. [PMID: 34696255 DOI: 10.3390/vaccines9101147] [Reference Citation Analysis]
31 Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BKJ, Chan YH, Sundar R, Soon YY. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 2022;376:e068632. [PMID: 35236664 DOI: 10.1136/bmj-2021-068632] [Reference Citation Analysis]
32 Shehab M, Abu-Farha M, Alrashed F, Alfadhli A, Alotaibi K, Alsahli A, Alphonse Thanaraj T, Channanath A, Ali H, Abubaker J, Almulla F. Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study. J Clin Med 2021;10:5362. [PMID: 34830644 DOI: 10.3390/jcm10225362] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, Bryant R, Begun J, Ward MG, Lewindon PJ, Connor SJ, Ghaly S, Christensen B. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 2021;3:212-28. [PMID: 34539248 DOI: 10.1002/ygh2.473] [Reference Citation Analysis]
34 Kappelman MD, Weaver KN, Boccieri M, Firestine A, Zhang X, Long MD; PREVENT-COVID Study Group. Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease. Gastroenterology 2021:S0016-5085(21)03127-9. [PMID: 34144046 DOI: 10.1053/j.gastro.2021.06.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Jena A, Mishra S, Deepak P, Kumar-M P, Sharma A, Patel YI, Kennedy NA, Kim AHJ, Sharma V, Sebastian S. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun Rev 2021;:102927. [PMID: 34474172 DOI: 10.1016/j.autrev.2021.102927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
36 Alexander JL, Kennedy NA, Lees CW, Ahmad T, Powell N; British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group. SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply. Lancet Gastroenterol Hepatol 2021;6:523-4. [PMID: 34119033 DOI: 10.1016/S2468-1253(21)00194-1] [Reference Citation Analysis]
37 Rodríguez-Martinó E, Medina-Prieto R, Santana-Bagur J, Santé M, Pantoja P, Espino AM, Sariol CA, Torres EA. Early immunologic response to mRNA COVID-19 vaccine in patients receiving biologics and/or immunomodulators. medRxiv 2021:2021. [PMID: 34545370 DOI: 10.1101/2021.09.11.21263211] [Reference Citation Analysis]
38 Whitaker HJ, Tsang RS, Byford R, Andrews NJ, Sherlock J, Pillai PS, Williams J, Button E, Campbell H, Sinnathamby M, Victor W, Anand S, Linley E, Hewson J, DArchangelo S, Otter AD, Ellis J, Hobbs RF, Howsam G, Zambon M, Ramsay M, Brown KE, de Lusignan S, Amirthalingam G, Bernal JL. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. J Infect 2022:S0163-4453(21)00664-2. [PMID: 34990709 DOI: 10.1016/j.jinf.2021.12.044] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Hadi YB, Thakkar S, Shah-Khan SM, Hutson W, Sarwari A, Singh S. COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States. Gastroenterology 2021:S0016-5085(21)03125-5. [PMID: 34144044 DOI: 10.1053/j.gastro.2021.06.014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Alexander JL, Kennedy NA, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Liu Z, Nice R, Bewshea C, D'mello A, Constable L, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Boyton RJ, Goodhand JR, Hart AL, Lees CW, Ahmad T, Powell N, Chukwurah I, Haq S, Shah P, Wilken-smith S, Ramanathan A, Patel M, Romanczuk L, King R, Domingo J, Shamtally D, Mendoza V, Sanchez J, Stark H, Knight B, Bee L, Estember C, Barnes A, Watkins D, Stone S, Kirkwood J, Parkinson M, Gardner-thorpe H, Covil K, Derikx L, Gros Alcalde B, Lee I, Cipriano B, Ruocco G, Baden M, Cooke G, Pollock K. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00005-x] [Reference Citation Analysis]
41 Cerna K, Duricova D, Lukas M, Machkova N, Hruba V, Mitrova K, Kubickova K, Kostrejova M, Teplan V, Vasatko M, Kastylova K, Lukas M. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study. Inflamm Bowel Dis 2021:izab301. [PMID: 34849919 DOI: 10.1093/ibd/izab301] [Reference Citation Analysis]
42 Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Khan H, Lechmere T, Malim MH, Meynell F, Pollock E, Sychowska K, Barker JN, Norton S, Galloway JB, Doores KJ, Tree T, Smith CH. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol 2021. [PMID: 34778846 DOI: 10.1016/S2665-9913(21)00333-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Magro F, Estevinho MM. COVID-19 Vaccines in IBD Patients: Particularities and Future Perspectives. J Crohns Colitis 2022:jjac042. [PMID: 35412580 DOI: 10.1093/ecco-jcc/jjac042] [Reference Citation Analysis]
44 Anand S, Montez-Rath ME, Han J, Garcia P, Cadden L, Hunsader P, Kerschmann R, Beyer P, Dittrich M, Block GA, Boyd SD, Parsonnet J, Chertow GM. Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis. medRxiv 2021:2021. [PMID: 34013281 DOI: 10.1101/2021.05.06.21256768] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Shehab M, Zurba Y, Al Abdulsalam A, Alfadhli A, Elouali S. COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study. Vaccines (Basel) 2021;10:55. [PMID: 35062716 DOI: 10.3390/vaccines10010055] [Reference Citation Analysis]
46 Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E. Impact of Low-Dose Methotrexate-Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis. Vaccines (Basel) 2021;9:883. [PMID: 34452007 DOI: 10.3390/vaccines9080883] [Reference Citation Analysis]